New Standard of Care for EGFR Mutation-Positive Advanced NSCLC New Standard of Care for EGFR Mutation-Positive Advanced NSCLC

Dr Jack West talks about the new role of osimertinib for NSCLC patients with EGFR mutation-positive acquired resistance.Medscape Oncology
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news